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Abstract 4-1BB(CD137) is a member of the tumor necrosis
factor receptor superfamily and provides a costimulatory signal
by interaction with 4-1BB ligand expressed on antigen-present-
ing cells. The expression of 4-1BB is known to be activation-
dependent. Here, we investigated the transcriptional machinery
required for T cell receptor (TCR) activation-dependent induc-
tion of 4-1BB expression in CD3-CEM cells treated with phor-
bol myristate acetate and ionomycin. Using 5P-deletion con-
structs of 4-1BB promoter in luciferase reporter assays, we
demonstrated that the transcriptional elements mediating 4-
1BB upregulation were located in the region between V0.9
and V1.1 kb from the translational start site. Characterization
of these sites by electrophoretic mobility shift assay and site-
directed mutagenesis revealed that nuclear factor UB (NF-UB)
and activating protein-1 (AP-1) are involved. MEK and c-Jun
N-terminal kinase-1 activity was required for activation-depen-
dent 4-1BB upregulation. Thus, NF-UB and AP-1 are involved
in the TCR stimulation-dependent transcriptional regulation of
the 4-1BB promoter.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: 4-1BB; CD137; T cell activation;
T cell receptor signal; Transcription factor
1. Introduction
Stimulation of T cells by T cell receptor (TCR) engagement
activates a cascade of signaling events. Following the sequen-
tial activation of lck, fyn, and ZAP-70 protein tyrosine kinase
[1,2], other biochemical signals are generated including those
derived from the phosphatidylinositol pathway [3] and a Ras-
activated cascade of serine/threonine kinases [4,5]. Stimulation
of the Ras GTP exchange molecule initiates a cascade of ki-
nase activity involving Raf, MEK and ERK kinases [6,7],
which lead to the activation of several transcription factors,
including activating protein-1 (AP-1) [8]. Phosphatidylinositol
bisphosphate is cleaved into diacylglycerol and inositol tris-
phosphate by activated phospholipase CQ1 [9]. Activation of
protein kinase C by diacylglycerol leads to activation of the
transcription factor nuclear factor UB (NF-UB) [10]. Inositol
trisphosphate leads to intracellular Ca2þ in£ux and subse-
quently the activation of the serine phosphatase, calcineurin
[11], which, in turn, mediates the activation of nuclear factor
of activated T cells (NFAT). These activated transcription
factors regulate the transcription of a number of genes includ-
ing cytokines like interleukin-2 (IL-2) [3], and many other
genes that lead to immune response and clonal expansion-
or activation-induced cell death.
One such gene product is 4-1BB (CD137), a cell surface
protein that is induced by various T cell activation signals
and provides a costimulatory signal by interaction with its
ligand (4-1BBL) expressed on antigen-presenting cells [12^
18]. Signals delivered to the T cell by the interaction of 4-
1BB with 4-1BBL can induce T cells to produce IL-2, prolif-
erate, and di¡erentiate [13,14,19,20], as well as protect T cells
from activation-induced cell death [21,22].
4-1BB is inducible through the TCR in the presence of
cytokines or in combination with CD28 ligation [23,24], or
anti-TCR monoclonal antibody (mAb), or anti-CD3 mAb
[25,26], or by stimulation with phorbol myristate acetate
and ionomycin (P/I) [27]. This induction could be inhibited
with cyclosporin A [25] or cycloheximide [26]. Actinomycin D
reduced 4-1BB mRNA levels in activated lymphocytes by 50%
within 30 min, demonstrating a relatively short half-life of this
mRNA [16].
Despite these ¢ndings, the transcriptional machinery con-
trolling 4-1BB induction has not been elucidated. Based on
the analysis of genomic DNA, 4-1BB is localized on chromo-
some 1p36 which contains the genes for other members of the
tumor necrosis factor (TNF) receptor superfamily such as
TNF-RII, OX40, CD30, and TRAMP/Apo3 [27]. Genomic
sequences proximal to the 4-1BB translational start site have
an absence of conventional TATA boxes. These are character-
istic of other members of the TNF^nerve growth factor re-
ceptor superfamily [28^31].
In this study, we have investigated the transcriptional ma-
chinery required for TCR activation-dependent induction of
4-1BB expression in CD3-CEM cells, a subclone of the CD4þ
T cell line, CCRF-CEM. 4-1BB was markedly upregulated in
these cells by P/I stimulation. Using deletion constructs of the
4-1BB promoter in luciferase reporter assays, we demonstrate
the presence of an activation-responsive sequence ofV200 bp
containing putative binding sites for transcription factors NF-
UB and AP-1. Characterization of these sites by electropho-
retic mobility shift assay (EMSA) and site-directed mutagen-
esis revealed that transcriptional activation of the 4-1BB gene
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upon stimulation with P/I requires NF-UB and AP-1 recruit-
ment to the promoter site.
2. Materials and methods
2.1. Cell lines and reagents
The CD4þ T cell line CCRF-CEM was obtained from ATCC and
cultured in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 Wg/ml penicillin, 100 U/ml streptomycin (Biowhittaker,
Walkersville, MD, USA). A CD3-positive population of CCRF-
CEM was isolated by MACS (data not shown) and was named
CD3-CEM. For TCR stimulation, anti-human CD3 mAb (BD Phar-
mingen, San Diego, CA, USA) was immobilized on plastic culture
dishes by incubating dishes at 4‡C with 10 Wg/ml in phosphate-bu¡-
ered saline overnight. Phorbol myristate acetate (20 ng/ml, Sigma, St.
Louis, MO, USA) and ionomycin (0.5 WM, Sigma) were also used to
activate CD3-CEM. PD98059 was purchased from Sigma. A mouse
mAb 4B4 against the human 4-1BB molecule [32] was used for £ow
cytometry, and MAG56 mAb [33] was used as an irrelevant, isotype-
matched control antibody. Goat Q-globulin was purchased from Pierce
(Rockford, IL, USA). pcDNA3-Flag-JNK1 (APF, T183A/Y185F)
[34] was kindly provided by Dr. H.-R.C. Kim, Wayne State Univer-
sity (Detroit, MI, USA).
2.2. Flow cytometry
Cells were harvested at determined time points and analyzed as
described in [35]
2.3. Reverse transcriptase polymerase chain reaction (RT-PCR)
CD3-CEM cells are cultured with P/I and harvested at 0, 12, 24, 36,
and 48 h. Total RNA was isolated from the cells using the RNeasy
mini kit (Qiagen, Valencia, CA, USA) as described in the user man-
ual. Total RNA 2.5 Wg was reverse transcribed into cDNA and the
enzymatic ampli¢cation by PCR was performed as described in [35].
Sense and antisense primers used in the PCR were as follows: for 4-
1BB, 5P-GGATTGTAAACAAGGTCAAG-3P and 5P-CACATCCTC-
CTTCTTCTTCT-3P. For PCR reaction, the sample was ¢rst dena-
tured at 95‡C for 3 min and ampli¢ed by 40 cycles of PCR (94‡C,
30 s; 55‡C, 30 s; 72‡C, 1 min), followed by 7 min at 72‡C for 4-1BB
or by 30 cycles of PCR for GAPDH. Equal aliquots of RT-PCR
product for 4-1BB (448 bp) and GAPDH (500 bp) were separated
on 1.5% agarose gels and stained with ethidium bromide.
2.4. Construction of 4-1BB promoter-luciferase plasmids
Human peripheral blood mononuclear cells were obtained from
peripheral blood of healthy donors by Ficoll density gradient centri-
fugation. Genomic DNA was isolated by the method of Gross-Bellard
et al. [36] and V1.7 kb of 4-1BB promoter was ampli¢ed by PCR
using a KpnI-HindIII-£anked primer set derived from genomic se-
quences (GenBank accession number NT_004454) upstream of the
4-1BB translational start site. The forward and reverse primers used
for PCR ampli¢cation from human genomic DNA were as follows
and underlines mean £anked KpnI or HindIII restriction enzyme se-
quences: forward, 5P-AGGTACCTGCCATGTTGGACGTCTAG-3P ;
and reverse, 5P-TAAGCTTGATGAAATCTGGCACAGGTA-3P.
ThisV1.7 kb PCR product was subcloned into luciferase-link report-
er plasmid, pGL3-Enhancer (Promega, Madison, WI, USA). To
generate smaller promoter fragments, plasmid pGL3E-1.7 kb was
used as a template during PCR by various 5P-£anking sequences
of the 4-1BB promoter gene as forward primers. For 1.1 kb,
5P-TGGTACCAATGCTTTGTCCTGGAGAGC-3P ; 1.0 kb, 5P-A-
GGTACCTGAACAGGGAGGTCTT-3P ; 0.9 kb, 5P-TGGTACCG-
AGACCCCGCCCCTG-3P ; 0.85 kb, 5P-AGGTACCTGAAGTCCT-
CTCG-3P ; 0.8 kb, 5P-AGGTACCAAGGTCTGTCCATCT-3P ; 0.55
kb, 5P-AGGTACCTGAACAGGGAGGTCTT-3P ; 0.5 kb, 5P-T-
GGTACCCAGCTAAAGGGGGAAGAGTG-3P. The 3P end of
each promoter fragment was the ¢rst nucleotide of the translational
start site. All PCR-derived constructs were con¢rmed by £uorescent
automated sequencing (Pangenomics, Seoul, Korea).
2.5. Generation of mutant 4-1BB promoter-reporter construct
Transcription factor binding mutants were created using overlap
extension PCR with the above forward and reverse primers for 1.1
kb and the following primers to incorporate a transcription factor
binding site mutation: NF-UB forward, 5P-TGTGGTGCGAATT-
TCCCATGAG-3P ; and reverse, 5P-CTCATGGGAAATTCGCACC-
ACA-3P. Proximal AP-1 forward, 5P-GCCCCTGGCTGAGTTGCC-
GCACT-3P ; and reverse, 5P-AGTGCGGCAACTCAGCCAGGGG-
C-3P. Distal AP-1 forward, 5P-GTCATCTGTGACAGGTCCTG-3P ;
and reverse, 5P-CAGGACCTGTCACAGATGAC-3P. All mutants
are veri¢ed by £uorescent automated sequencing (Pangenomics).
2.6. Transient transfection and luciferase assay
Di¡erent 4-1BB promoter constructs were transiently transfected
into CD3-CEM cells using DMRIE-C (Life Technologies) as de-
scribed in the user manual. pCMVL (BD Clontech, Palo Alto, CA,
USA) was cotransfected to normalize transfection e⁄ciencies. In all
cases, the total amount of DNA in each transfection was kept equal
by the addition of control DNA (pcDNA3) where appropriate. Cells
(8U105 cells/well) were incubated with DNA (3 Wg) and DMRIE-C (3
Wl). For JNK1, pcDNA3-Flag-JNK1 (T183A/Y185F) was cotrans-
fected with 1.1 kb promoter plasmid and pCMVL. After 4^5 h, trans-
fected cells were incubated with phorbol myristate acetate 20 ng/ml
and ionomycin 0.5 WM for 36^40 h. For anti-CD3 stimulation, trans-
fected cells were transferred to the wells coated by 10 Wg/ml/well of
anti-human CD3 mAb and cultured for 36^40 h. Cells were harvested
and washed with phosphate-bu¡ered saline, and lysed in 150 Wl of
reporter lysis bu¡er (Promega). Cell debris was removed by centrifu-
gation, and the supernatant was used in the luciferase assay and L-
galactosidase (L-gal) assay. Luciferase activity was measured in trip-
licate using the Dual Luciferase Assay kit (Promega) following the
manufacturer’s recommendations using a luminometer, Luminoskan
Ascent (Thermo Labsystems USA, Franklin, MA, USA). Luciferase
activity was normalized by L-gal activity for each data point.
2.7. EMSA
CD3-CEM 4U107 cells were stimulated with P/I and harvested at 0,
2, and 4 h. Nuclear extracts were prepared according to the method
by Schreiber et al. [37]. Wild type and mutant oligonucleotides con-
taining NF-UB, proximal AP-1 and distal AP-1 sequences of the 4-
1BB promoter were synthesized (Cosmogentech, Seoul, Korea). The
probe corresponding to the distal AP-1 site (31067 to 31048) was 5P-
GTATCTGTGACACATCCTG-3P (mutant: CACGG); NF-UB
(3915 to 3894), 5P-TGTGTGGGAATTTCCCATGAG-3P (mutant:
GCC); proximal AP-1 (3888 to 3876), 5P-GCCCCTGGCTGAG-
TCACCGCACT-3P (mutant: CACTG). The UB site in the U light
chain enhancer region used as a control probe (5P-AGTTGAGGG-
GACTTTCCCAGGC-3P) and AP-1 control probe (5P-CGCTTGAT-
GAGTCGCCGAA-3P) were purchased from Promega. Oligonucleo-
tides were annealed to make double-stranded target DNA and then
end-labeled by [Q-32P]ATP. For EMSAs, 10 Wg of nuclear extracts was
incubated with V100 000 cpm (40 fmol) of the indicated Q-32P-end-
labeled probes for 30 min at room temperature. For competition
assays, excess unlabeled wild type, mutant, or control oligonucleotides
for transcription factor binding sites were added. For antibody-medi-
ated supershift assays, either anti-p50 or p65 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) antibodies were co-incubated. The reac-
tion mixtures were loaded on a 4.5^5.5% polyacrylamide non-
denaturing gels in 0.5UTBE bu¡er and electrophoresed for 2 h at
150 V. The gels were dried and exposed to autoradiographic ¢lm.
3. Results
3.1. Induction of 4-1BB expression in CD3-CEM cells by
T-cell activation
To study the transcription mechanisms controlling 4-1BB
expression in response to signals through TCR, we ¢rst at-
tempted to select a human T cell line, which highly expresses
4-1BB protein on the cell surface upon activation. Flow cyto-
metry analyses have shown that 4-1BB induction was greater
in CCRF-CEM than any other T cell lines, such as Jurkat,
Molt-4, and SUPT-1 (data not shown). Therefore, we isolated
CD3þ population of CCRF-CEM (CD3-CEM) and used in
this study. To assess the induction of 4-1BB following TCR
stimulation, CD3-CEM cells were stimulated with anti-CD3
mAb or P/I that mimic TCR-mediated signaling events for
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various times, and protein and mRNA expression was deter-
mined with £ow cytometry and RT-PCR, respectively. Surface
4-1BB expression is upregulated after anti-CD3 mAb and P/I
treatment. Increased 4-1BB was detectable at 12 h post stim-
ulation, reached maximal levels at 24 h, and declined to base-
line levels by 48 h in cells stimulated with anti-CD3 mAb (Fig.
1A). In cells treated with P/I, 4-1BB was induced after 24 h
and the level reached 63% at 48 h (Fig. 1B). The amount of 4-
1BB mRNA was also increased after P/I treatment. 4-1BB
mRNA was hardly detected at 0 h, the level increased signi¢-
cantly at 8 h and the increased level was maintained up to 48
h (Fig. 1C). It was reported that 4-1BB mRNA has a relative
short half-life, 30 min, and induction of 4-1BB mRNA was
primarily due to increased transcription [16]. These results
suggested that the induction of surface 4-1BB of CD3-CEM
by TCR activation is due to the upregulation of transcription.
3.2. A 251 bp region in the 4-1BB promoter is required for
transcriptional activation
Putative transcription factor binding sites, which include
NFAT, NF-UB and AP-1 elements, were identi¢ed in the 5P-
upstream region of the 4-1BB translational start site using
MatInspector V2.2 software (Fig. 2). We cloned a 1.7 kb
size fragment of the putative 4-1BB promoter by PCR from
human genomic DNA and inserted it into the luciferase re-
porter plasmid, pGL3-enhancer. Within this 1.7 kb region, 5P-
untranslated exon 1 and partial exon 2 are localized. To in-
vestigate the requirements for TCR-mediated expression of 4-
1BB, the reporter construct was transiently transfected into
CD3-CEM cells and its expression was measured after cell
stimulation. A 39 h stimulation with immobilized anti-CD3
mAb induced 4-1BB reporter activity six-fold over that in
unstimulated controls (Fig. 3B). When the cells were stimu-
lated with P/I, the response was comparable to that seen with
anti-CD3 stimulation. To determine which segment(s) of the
5P-untranslated region of the 4-1BB gene is important for
transcriptional activation, six deletion promoter constructs
of various sizes (Fig. 3A) were transiently transfected and lu-
ciferase activity was measured after anti-CD3 mAb or P/I
stimulation. The results shown in Fig. 3B indicate that stim-
ulus-dependent transcriptional activity was detected in con-
structs containing promoter sequences from 3866 bp to
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
Fig. 1. Time course of induction of 4-1BB in CD3-CEM cells treated with anti-CD3 mAb or P/I. A: Cells were incubated in the tissue culture
plates coated with anti-CD3 mAb and harvested at the indicated time, and 4-1BB expression was analyzed by £ow cytometry. Isotype-matched
control antibody, MAG56 staining is represented as a dashed line. B: Cells stimulated with P/I were harvested at the indicated time, and 4-
1BB expression was analyzed as in A. C: Cells treated with P/I were harvested at the indicated time. The total RNA was extracted and ana-
lyzed for relative levels of 4-1BB mRNA by RT-PCR. GAPDH was used to normalize for template quantity. Data were representative of at
least two independent experiments.
           
                               
                     
                        
 
 
 
  
  
 
  
   
           
  
            
 
 
     
Fig. 2. Nucleotide sequence of the 5P-upstream region of the human
4-1BB gene. The translational start site is designated +1 and num-
bers indicate nucleotide locations with respect to the translational
start site. An arrow indicates the transcription start site and the
exon is underlined. The boxes indicate the predicted transcription
factor binding sites and gray shadowed regions represent the loca-
tion of primers used in cloning of 4-1BB 5P-deletant promoters.
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31117 bp and a maximal induction of 23-fold was observed in
the construct containing up to 31117 bp, after P/I stimula-
tion. The transcription activity of 31741 bp is similar to that
of 31117 bp. These results suggest that the region between
31117 and 3866 relative to the translation initiation site is
involved in signal-induced transcriptional activation and con-
tains enhancer element(s) necessary for activation responsive-
ness. Sequence analysis within this region demonstrated the
presence of consensus elements for several transcription fac-
tors including NF-UB, AP-1, GATA and SP1 (Fig. 2).
3.3. AP-1 and NF-UB bind to the putative 4-1BB promoter
binding site
To analyze whether transcription factors are involved in the
activation-dependent upregulation of the 4-1BB promoter
within the 31117 and 3866 region, EMSA analyses were
carried out. Nuclear extracts prepared from unactivated and
P/I-stimulated CD3-CEM cells were incubated with 32P-la-
beled probe spanning the 4-1BB promoter regions of 31067
to 31048 (putative distal AP-1), 3915 to 3894 (putative NF-
UB), and 3888 to 3876 (putative proximal AP-1). A time
course analysis revealed the presence of complexes binding
to these region and maximum binding was detected after 2 h
stimulation with each probe (Figs. 4 and 5). The binding
was competed out with 25- and 50-fold excess of unlabeled
probes. Unlabeled probes containing mutations in the puta-
tive binding site(for distal AP-1, TGACACACTGACAGG;
for NF-UB, GGGAACGCGAA; for proximal AP-1,
TGAGTCACTGAGTTG) did not interfere with DNA bind-
ing of the protein complexes (Figs. 4 and 5). To determine the
nature of each complex binding, competition was also carried
out with 25- or 50-fold excess of the oligonucleotides contain-
ing the NF-UB site in U light chain enhancer region and AP-1
control elements. As shown in Fig. 4, putative distal and
proximal AP-1 binding was inhibited by AP-1-speci¢c oligo-
nucleotides, but not NF-UB-speci¢c oligonucleotides, indicat-
ing the speci¢city of AP-1 binding at the 31067 to 31048 and
3888 to 3876 sequences. As shown in Fig. 5A, putative NF-
UB binding was inhibited by unlabeled probe (lanes 7 and 8),
but not mutant oligonucleotide or AP-1 control DNA (lanes
9^12). To characterize the protein complex that binds to a
putative NF-UB sequence, we repeated the EMSAs in the
presence of antibodies against p65 and p50 of the NF-UB
family. Antibodies speci¢c for p65 and p50 caused the super-
shifted, slower migrating DNA^protein complex (Fig. 5B).
These results indicate that the nuclear protein complex, which
binds to the putative NF-UB binding sequence, contains at
least p50 and p65 of NF-UB and P/I stimulation increases
p65 binding more than p50 binding. When we use the probes
containing potential Sp1 and GATA-1 binding sites, DNA^
protein complexes were not detected (data not shown).
3.4. AP-1 and NF-UB promoter elements are critical for
regulation of 4-1BB expression in activated T lymphocytes
After showing that the AP-1 and NF-UB present in nuclear
extracts are major components of the nuclear protein complex
that binds to the 4-1BB promoter sequences, we next inves-
tigated whether these AP-1 and NF-UB binding sites are im-
portant for the regulation of 4-1BB expression. We mutated
each distal and proximal AP-1 and NF-UB site in the context
of the 1117 bp 4-1BB promoter-reporter. These mutant con-
structs were tested for their ability to induce reporter gene
expression upon T cell activation with anti-CD3 or P/I treat-
ment. As shown in Fig. 6, mutation of the NF-UB and AP-1
                      
 
 
 
 
 
 
 
 
 
 
  
 
  
  
  
 
   
      
Fig. 3. Characterization of 4-1BB promoter by reporter analysis. A: 4-1BB promoter deletion constructs used in reporter analysis. 4-1BB pro-
moter DNA sequences with various 5P-deletions were cloned upstream of the luciferase reporter gene in pGL3-enhancer. Numbers indicate nu-
cleotide locations with respect to the translational start site of the 4-1BB gene. B: Analysis of the promoter region of the human 4-1BB gene.
CD3-CEM cells were transiently transfected with various 5P-deletion promoter-reporter constructs and pCMVL. Cells were treated with anti-
CD3 mAb (left panel) or P/I (right panel) and reporter activity was determined after 39 h. Transfection e⁄ciencies were normalized by L-gal
activity and the results are represented as relative luciferase activity. Error bars represent the standard deviation of triplicate samples and data
are representative of at least three independent experiments.
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sites had a profound e¡ect on T cell activation-mediated 4-
1BB expression (9 67.9% reduction), further supporting the
idea that AP-1 and NF-UB are required for optimal activation
of the 4-1BB transcription induced by T cell activation sig-
nals.
3.5. MEK and JNK1 activities are required in activation-
dependent 4-1BB upregulation
We explored the possible role of protein kinase MEK and
JNK1 in the induction of 4-1BB. T cell receptor ligation acti-
vates the early genes fos and jun that heterodimerize and bind
to the AP-1 site to regulate IL-2 and other cytokine gene
transcription [38]. Since Erk contributes to fos activation,
the potential role of the Ras/MEK/Erk pathway was de¢ned
by PD98059, a pharmacological inhibitor of MEK [39]. As
shown in Fig. 7A, 1.1 kb of 4-1BB promoter activity was
more reduced after P/I plus PD98059 than after P/I stimula-
tion only. Phosphorylation of c-Jun by JNK/SAPK is re-
quired for AP-1-dependent promoter activity [38]. DN-
JNK1 (T183A/Y185F) expression inhibited c-Jun phosphory-
lation e¡ectively (data not shown). To study the e¡ect of
JNK1 on 4-1BB promoter activity, we cotransfected the 1.1
kb of 4-1BB promoter with DN-JNK1 (T183A/Y185F) ex-
pression vector. P/I-activated CD3-CEM cells transiently
transfected with DN-JNK1 showed a dose-dependent decrease
in 4-1BB promoter activity with increasing DN-JNK1 concen-
tration (Fig. 7B). As shown in Fig. 7C, the reporter activity
was signi¢cantly reduced in anti-CD3 mAb stimulation as well
as P/I activation. Taken together, these results strongly sup-
port that the MEK and JNK pathways are involved in TCR
activation-dependent 4-1BB expression.
4. Discussion
In this study, we have shown that the transcription factors
NF-UB, and AP-1 are involved in induction of 4-1BB expres-
sion through TCR signaling.
4-1BB is known to be expressed primarily on activated
CD4þ and CD8þ T cells and 4-1BB/4-1BBL binding delivers
the costimulatory signals to T cells synergized with CD28 or
in the absence of CD28 [17,40,41]. When signals through the
TCR are weak, 4-1BB co-stimulation is not as e¡ective as
  
              
      
 
 
 
 
 
 
 
 
 
        
  
  
 
   
   
 
           
     
 
 
 
 
 
 
 
 
 
      
 
 
 
   
 
Fig. 4. EMSA of putative AP-1 binding sites. CD3-CEM cells were activated with P/I, nuclear extracts were harvested, and EMSA analysis
was performed with indicated 32P-labeled probe. A: Analysis of protein binding to a putative distal AP-1 site located at 31067 to 31048.
Time course analysis (0, 2, 4 h) of DNA^protein complex binding is shown in the left panel, lanes 1^4. Cold competition was performed with
2 h activated CD3-CEM cell nuclear extracts with 25- and 50-fold excess of wild type probe (WT, lanes 7 and 8), mutant probe (M, lanes 9
and 10), consensus oligonucleotides for transcription factor AP-1 (lanes 11 and 12) or NF-UB (lanes 13 and 14). B: Analysis of protein binding
to a putative proximal AP-1 site at 3888 to 3876. Time course analysis is shown in the left panel, lanes 1^3. Cold competition was performed
with 2 h activated CD3-CEM cell nuclear extracts with 25- and 50-fold excess of wild type probe (WT, lanes 6 and 7), mutant probe (M, lanes
8 and 9), 50-fold of consensus oligonucleotides for transcription factor AP-1 (lane 10) or NF-UB (lane 11). n.s., non-speci¢c binding.
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CD28 costimulation in the induction of IL-2 [41]. This may be
due to the fact that 4-1BB must be upregulated during the
initial T cell activation event ^ in contrast to CD28, which is
expressed constitutively. While much has been learned about
the molecular mechanisms that transduce activation signals
following 4-1BB/4-1BBL interactions [42^44], little is yet
understood about how the expression of 4-1BB is regulated.
Because of the important role played by 4-1BB in control of
T lymphocyte activation, we became interested in how this
molecule was regulated at the level of transcription in human
T cells.
We therefore constructed 4-1BB promoter-reporter to ad-
dress questions about the transcription factors that are in-
volved in driving 4-1BB following TCR engagement. The 4-
1BB surface expression level following P/I activation was 63%
in the CD3-CEM cell line (Fig. 1), this was enough to eluci-
date the linkage between TCR activation and 4-1BB upregu-
lation. Our ¢rst experiments were designed to show that the
V1.7 kb reporter mirrored expression of the endogenous
gene. We demonstrated this to be true in the CD3-CEM cell
line whether cells are stimulated through their TCR or with
pharmacological agents, P/I (Fig. 3). Although the transcrip-
  
 
     
  
   
 
 
 
 
 
 
 
 
        
   
 
 
 
      
    
  
   
 
Fig. 5. EMSA of putative NF-UB binding site at 3915 to 3894. A: CD3-CEM cells were stimulated with P/I for the indicated time, nuclear
extracts were harvested and EMSA was performed with 32P-labeled probe (left panel, lanes 2^4). Cold competition assay (lanes 5^12) was per-
formed by incubating CD3-CEM nuclear extracts obtained from cells stimulated with P/I for 2 h with 25- and 50-fold excess of wild type probe
(WT, lanes 7 and 8), AP-1 control oligonucleotide (lanes 9 and 10), or mutant probe (lanes 11 and 12). B: Antibody-mediated supershift analy-
ses of NF-UB site binding proteins. CD3-CEM nuclear extracts prepared from cells of 2-h stimulation were subjected to EMSA analysis in the
absence (lane 5) or presence of the indicated speci¢c antibody of NF-UB subunit (lanes 2 and 3), or goat Q-globulin (N.R.). Arrows indicate the
identity of the supershift complexes. n.s., non-speci¢c binding.
    
      
  
  
  
  
  
Fig. 6. The distal AP-1, NF-UB, and proximal AP-1 sites are required for optimal 4-1BB promoter activity in stimulated CD3-CEM cells. 1.1
kb of di¡erent mutant promoters were generated as described in Section 2. CD3-CEM cells were transiently transfected with the di¡erent 1.1
kb regions of promoter-reporter constructs which are the wild type 1.1 kb (1.1 kb), distal AP-1 mutant (M-dAP1), NF-UB mutant (M-UB), and
proximal AP-1 mutant (M-pAP1), or with promoterless luciferase reporter (mock) and pCMVL. The transfectants were left unstimulated (no
treat), or were stimulated with P/I or plate-bound anti-CD3 mAb for 23 h and 45 h respectively. Cells were then lysed and assayed for lucifer-
ase activity. Data are represented as relative luciferase activity and transfection e⁄ciencies were normalized by L-gal activity. One representative
experiment of at least three performed is shown.
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tion initiation site was not experimentally determined, the
ability of this construct to drive luciferase expression suggests
that a functional promoter is located within the 1.7 kb region.
The comparison among the published 4-1BB mRNA sequen-
ces (GenBank accession numbers U03397, 1415 bp; L12964,
1419 bp; and NM_001561, 1937 bp) supported that the tran-
scription start site was at around 833 bp upstream from the
translation start site. In experiments with 5P-deletion promoter
constructs, the change in reporter activity in cells transfected
with various constructs also paralleled in both stimuli as the
promoter was shortened below 1.1 kb (Fig. 3). We revealed
that the 3866 bp to 31117 bp region of 4-1BB gene is im-
portant for signal-induced transcriptional activation and iden-
ti¢ed several potential regulatory regions including AP-1, NF-
UB, GATA1 and SP1 in this region (Fig. 2). However, we
could not detect P/I-inducible GATA1 or SP1 binding when
these sites were used as probes in EMSA analyses (data not
shown).
Our results demonstrated that the 4-1BB promoter contains
a NF-UB binding site at position 3911 to 3898 relative to the
4-1BB translational start site. The prototypic form of NF-UB
is a heterodimer complex containing NF-UB1-p50 or NF-UB2-
p52 in combination with a transactivating subunit such as c-
Rel or RelA(p65) [45]. Each NF-UB-Rel family member con-
tains a conserved N-terminal region responsible for DNA
binding, dimerization, and IUB interaction. NF-UB-responsive
genes are transactivated by the C-terminal domain of dimeric
NF-UB-Rel family members. Our EMSA analyses showed that
nuclear proteins that bind to the 4-1BB NF-UB sequence are
induced in CD3-CEM cells stimulated with P/I. Competition
assay with excess unlabeled probe for NF-UB and control AP-
1 or UB site in the U light chain enhancer region identi¢ed the
induced protein as NF-UB and indicated speci¢city of the
binding.
An antibody-mediated supershift assay showed that the
NF-UB probe (3915 to 3894) was bound by p50 and p65
(RelA) (Fig. 5). Because the p50/p50 homodimer lacks the
ability to activate genes, it is suggested that upon activation,
the p50/p65 heterodimer translocates into the nucleus and
bind the 4-1BB site, and this, in turn, activates 4-1BB pro-
moter activity. However, it remains possible that there is co-
operation of other NF-UB family members such as p52, RelB,
and c-Rel. The dramatic reduction in transcriptional 4-1BB
promoter activity is observed with a 1.1 kb 4-1BB promoter-
reporter containing site-directed mutagenesis in NF-UB bind-
ing site (85.4% reduction) (Fig. 6). Wang et al. reported that
the level of 4-1BB expression and the percentage of 4-1BB-
expressing T cells is higher in HIV-1þ individuals after T-cell
stimulation than in HIV-13 individuals [46]. This phenome-
non might be due to the fact that both HIV-1 binding and
gp120-mediated CD4 cross-linking can induce NF-UB [47].
This result further supports our suggestion that NF-UB plays
a critical role in stimulus-induced 4-1BB gene expression in
T cells.
Our result showed that two AP-1 binding sites located at
the 3866 and 31117 bp regions of the 4-1BB promoter are
critically involved in the induction of 4-1BB in stimulated
CD3-CEM cells. AP-1 complexes can consist of di¡erent di-
meric Fos and Jun family members and exhibit variable DNA
binding speci¢city. Although Jun/Jun homodimers and Fos/
Jun heterodimers can transactivate AP-1 sites, Fos/Jun heter-
odimers are more potent transactivators [48]. In EMSA, the
AP-1 probe^protein complex band intensity was not decreased
by the competitor oligonucleotides containing the NF-UB
binding site but AP-1 consensus elements (Fig. 4). This was
con¢rmed by site-directed mutagenesis in distal and proximal
AP-1 sites. Each AP-1 mutant promoter construct resulted in
signi¢cant reduction of 4-1BB promoter activity (Fig. 6). The
results show that the proximal AP-1 site is a more critical
binding site than the distal site and suggest that the proximal
AP-1 site could be involved in the constitutive activity of 4-
1BB promoter as shown in EMSA, 0 time data (Fig. 4A).
PD98059, a pharmacological inhibitor of MEK, or DN-
JNK1 (T183A/Y185F) expression reduced 4-1BB promoter
activity in activated CD3-CEM (Fig. 7), further supporting
the idea that the transcriptional activation signal through
        
     
 
       
       
 
       
        
Fig. 7. MEK and JNK1 activity is required for activation-induced 4-1BB promoter activity. A: 4-1BB promoter 1.1 kb (1 Wg) was transfected.
The transfected CD3-CEM cells were stimulated with P/I or P/I plus PD98059 (50 WM). Results shown are the average of three independent ex-
periments and the standard deviations are represented as error bars. B: Dose-dependent inhibition of P/I-inducible 4-1BB promoter activity by
DN-JNK1. Increasing amounts of DN-JNK1 (T183A/Y185F) expression plasmid were cotransfected with 4-1BB promoter 1.1 kb (1 Wg). The
total amount of DNA in each transfection was kept equal by the addition of empty vector, pcDNA3. Transfected cells were activated with P/I
and luciferase activity was measured after 22^24 h. C: 4-1BB promoter 1.1 kb (1 Wg) and DN-JNK1 (4 Wg) or control DNA (4 Wg) were co-
transfected. Cells were activated with P/I (left panel) or anti-CD3 mAb (right panel) and analyzed as in A. Transfection e⁄ciencies were nor-
malized by L-gal activity and the results are represented as relative luciferase activity. Results shown are representative of at least three inde-
pendent experiments.
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the TCR is mediated by the MEK/Erk and JNK/SAPK path-
ways, and the 4-1BB promoter is an AP-1-dependent pro-
moter.
Collectively, our studies clearly demonstrate a critical role
for NF-UB and AP-1 in 4-1BB upregulation through TCR
activation, although other transcriptional or posttranscrip-
tional processes may also be operative. The elucidation of
the role of these transcription factors not only gives us in-
sights into the relationships between TCR activation and sig-
naling pathway into the costimulatory molecules, but also
provides strategies aimed toward its manipulation in inappro-
priate 4-1BB and 4-1BBL interactions, including rheumatoid
arthritis [49] and antigen-speci¢c immune regulation [50].
Acknowledgements: We thank Dr. Dae-Myung Jue, the Catholic Uni-
versity of Korea and Dr. R. Ward, U.S. Environmental Protection
Agency, for critically reading the manuscript. This work was sup-
ported by a Rheumatism Research Center Grant by the Korean Sci-
ence and Engineering Foundation (#R11-2002-098-03002-0).
References
[1] Chan, A.C. and Shaw, A.S. (1996) Curr. Opin. Immunol. 8, 394^
401.
[2] Wange, R.L. and Samelson, L.E. (1996) Immunity 5, 197^205.
[3] Weiss, A. and Littman, D.R. (1994) Cell 76, 263^274.
[4] Downward, J., Graves, J.D., Warne, P.H., Rayter, S. and Can-
trell, D.A. (1990) Nature 346, 719^723.
[5] Downward, J., Graves, J. and Cantrell, D. (1992) Immunol. To-
day 13, 89^92.
[6] Izquierdo, M., Leevers, S.J., Marshall, C.J. and Cantrell, D.
(1993) J. Exp. Med. 178, 1199^1208.
[7] Izquierdo, M., Bowden, S. and Cantrell, D. (1994) J. Exp. Med.
180, 401^406.
[8] Rothenberg, E.V. and Ward, S.B. (1996) Proc. Natl. Acad. Sci.
USA 93, 9358^9365.
[9] Nishibe, S., Wahl, M.I., Hernandez-Sotomayor, S.M., Tonks,
N.K., Rhee, S.G. and Carpenter, G. (1990) Science 250, 1253^
1256.
[10] Jamieson, C., McCa¡rey, P.G., Rao, A. and Sen, R. (1991)
J. Immunol. 147, 416^420.
[11] Clipstone, N.A. and Crabtree, G.R. (1992) Nature 357, 695^697.
[12] Goodwin, R.G., Din, W.S., Davis-Smith, T., Anderson, D.M.,
Gimpel, S.D., Sato, T.A., Maliszewski, C.R., Brannan, C.I.,
Copeland, N.G., Jenkins, N.A., Farrah, T., Armitage, R.J.,
Fanslow, W.C. and Smith, C.A. (1993) Eur. J. Immunol. 23,
2631^2641.
[13] Alderson, M.R., Smith, C.A., Tough, T.W., Davis-Smith, T.,
Armitage, R.J., Falk, B., Roux, E., Baker, E., Sutherland,
G.R. and Din, W.S. (1994) Eur. J. Immunol. 24, 2219^2227.
[14] DeBenedette, M.A., Chu, N.R., Pollok, K.E., Hurtado, J., Wade,
W.F., Kwon, B.S. and Watts, T.H. (1995) J. Exp. Med. 181, 985^
992.
[15] Pollok, K.E., Kim, Y.J., Hurtado, J., Zhou, Z., Kim, K.K. and
Kwon, B.S. (1994) Eur. J. Immunol. 24, 367^374.
[16] Schwarz, H., Valbracht, J., Tuckwell, J., Von Kempis, J. and
Lotz, M. (1995) Blood 85, 1043^1052.
[17] DeBenedette, M.A., Shahinian, A., Mak, T.W. and Watts, T.H.
(1997) J. Immunol. 158, 551^559.
[18] Schwarz, H., Blanco, F.J., Von Kempis, J., Valbracht, J. and
Lotz, M. (1996) Blood 87, 2839^2845.
[19] Hurtado, J.C., Kim, S.H., Pollok, K.E., Lee, Z.H. and Kwon,
B.S. (1995) J. Immunol. 155, 3360^3367.
[20] Saoulli, K., Lee, S.Y., Cannons, J.L., Yeh, W.C., Santana, A.,
Goldstein, M.D., Bangia, N., DeBenedette, M.A., Mak, T.W.,
Choi, Y. and Watts, T.H. (1998) J. Exp. Med. 187, 1849^
1862.
[21] Hurtado, J.C., Kim, Y.J. and Kwon, B.S. (1997) J. Immunol.
158, 2600^2609.
[22] Takahashi, C., Mittler, R.S. and Vella, A.T. (1999) J. Immunol.
162, 5037^5040.
[23] Pollok, K.E., Kim, Y.H., Zhou, Z., Hurtado, J., Kim, K.K.,
Pickard, R.T. and Kwon, B.S. (1993) J. Immunol. 150, 771^781.
[24] Pollok, K.E., Kim, S.H. and Kwon, B.S. (1995) Eur. J. Immunol.
25, 488^494.
[25] Kwon, B.S., Kestler, D.P., Eshhar, Z., Oh, K.O. and Wakulchik,
M. (1989) Cell. Immunol. 121, 414^422.
[26] Kwon, B.S., Kim, G.S., Prystowsky, M.B., Lancki, D.W., Sa-
bath, D.E., Pan, J.L. and Weissman, S.M. (1987) Proc. Natl.
Acad. Sci. USA 84, 2896^2900.
[27] Garni-Wagner, B.A., Lee, Z.H., Kim, Y.J., Wilde, C., Kang,
C.Y. and Kwon, B.S. (1996) Cell. Immunol. 169, 91^98.
[28] Kemper, O. and Wallach, D. (1993) Gene 134, 209^216.
[29] Rothe, J., Bluethmann, H., Gentz, R., Lesslauer, W. and Stein-
metz, M. (1993) Mol. Immunol. 30, 165^175.
[30] Santee, S.M. and Owen-Schaub, L.B. (1996) J. Biol. Chem. 271,
21151^21159.
[31] Sehgal, A., Patil, N. and Chao, M. (1988) Mol. Cell. Biol. 8,
3160^3167.
[32] Lee, S.H., Lee, N.G., Suh, S.Y., Kim, J.G., Choi, E.C. and
Kang, C.Y. (1996) Mol. Cells 6, 161^168.
[33] Kang, C.Y., Hariharan, K., Nara, P.L., Sodroski, J. and Moore,
J.P. (1994) J. Virol. 68, 5854^5862.
[34] Yu, J., Deuel, T.F. and Kim, H.-R.C. (2000) J. Biol. Chem. 275,
19076^19082.
[35] Kim, K.M., Kim, H.W., Kim, J.O., Baek, K.M., Kim, J.G. and
Kang, C.Y. (2002) Immunology 107, 472^479.
[36] Gross-Bellard, M., Oudet, P. and Chambon, P. (1973) Eur. J.
Biochem. 36, 32^38.
[37] Schreiber, E., Matthias, P., Muller, M.M. and Scha¡ner, W.
(1989) Nucleic Acids Res. 17, 6419.
[38] Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M. and Ben-
Neriah, Y. (1994) Cell 77, 727^736.
[39] Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. and Saltiel,
A.R. (1995) Proc. Natl. Acad. Sci. USA 92, 7686^7689.
[40] Chu, N.R., DeBenedette, M.A., Stiernholm, B.J., Barber, B.H.
and Watts, T.H. (1997) J. Immunol. 158, 3081^3089.
[41] Saoulli, K., Lee, S.Y., Cannona, J.L., Yeh, W.C., Santana, A.,
Goldstein, M.D., Bangia, N., DeBenedette, M.A., Mak, T.W.,
Choi, Y. and Watts, T.H. (1998) J. Exp. Med. 187, 1849^1862.
[42] Cannons, J.L., Hoe£ich, K.P., Woodgett, J.R. and Watts, T.H.
(1999) J. Immunol. 163, 2990^2998.
[43] Cannons, J.L., Choi, Y. and Watts, T.H. (2000) J. Immunol. 165,
6193^6204.
[44] Kwon, B.S., Moon, C.H., Kang, S., Seo, S.K. and Kwon, B.S.
(2000) Mol. Cells 10, 119^126.
[45] Verma, I.M., Stevenson, J.K., Schwartz, E.M., Van Antwerp, D.
and Miyamoto, S. (1995) Genes Dev. 9, 2723^2735.
[46] Wang, S., Kim, Y.-J., Bick, C., Kim, S.H. and Kwon, B.S. (1998)
AIDS Res. Hum. Retroviruses 14, 223^231.
[47] Briant, L., Coudronniere, N., Hebmann-Robert, V., Benkirane,
M. and Devaux, C. (1996) J. Immunol. 156, 3994^4004.
[48] Ryseck, R.P. and Bravo, R. (1991) Oncogene 6, 533^542.
[49] Michel, J., Langstein, J., Hofstadter, F. and Schwarz, H. (1998)
Eur. J. Immunol. 28, 290^295.
[50] Hong, H.J., Lee, J.W., Park, S.S., Kang, Y.J., Chang, S.Y., Kim,
K.M., Kim, J.O., Murthy, K.K., Payne, J.S., Yoon, S.K., Park,
M.J., Kim, I.C., Kim, J.G. and Kang, C.Y. (2000) J. Immun-
other. 23, 613^621.
FEBS 27168 11-4-03
J.-O. Kim et al./FEBS Letters 541 (2003) 163^170170
